Escaline

From PsychonautWiki
Jump to: navigation, search
Escaline
Escaline.png
Chemical Nomenclature
Common names Escaline
Substitutive name 3,5-methoxy-4-ethoxyphenethylamine
Systematic name 2-(4-Ethoxy-3,5-dimethoxy-phenyl)-ethylamine
Routes of Administration



Oral
Dosage
WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity.
Threshold < 25 mg
Light 25 - 50 mg
Common 50 - 100 mg
Strong 100 - 150 mg
Heavy 150 mg +
Duration
Total 8 - 12 hours
Onset 90 - 120 minutes
Afterglow 3 - 5 hours









Summary sheet: Escaline

Escaline, or 3,5-methoxy-4-ethoxyphenethylamine, is a psychedelic drug and entheogen of the phenethylamine class of compounds. Escaline was first synthesized and reported in the scientific literature by Benington, et al., in 1954, but was later re-examined in the laboratory of David E. Nichols who prepared a series of mescaline analogues that includes escaline, proscaline, and isoproscaline.

The effects of escaline were first described by Alexander Shulgin in his book PiHKAL: A Chemical Love Story. He lists the dosage range as 40mg to 60mg orally and describes the duration of action to be 8 - 12 hours.[1] Shulgin states that escaline “differs from mescaline in that the onset of action is quicker (within the first hour) and there is no nausea noted, but otherwise the time course, and much of the qualitative content, is quite similar.”. [2]

Chemistry

Molecule.svg

This chemistry section is incomplete.

You can help by adding to it.

Escaline is the phenethylamine analog of 3C-E and the 4-ethoxy analog of mescaline.

Pharmacology

Escaline's agonist activity at the serotonin 5-HT2A receptor is known to be 5-8 times greater than that of mescaline. [3][4] The effects of this compound are believed to come from its efficacy at the 5-HT2A receptor as a partial agonist. However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.

Subjective effects

The effects listed below are based upon the subjective effects index and personal experiences of PsychonautWiki contributors. The listed effects will rarely (if ever) occur all at once, but heavier dosages will increase the chances and are more likely to induce a full range of effects.

Physical effects

Cognitive effects

Visual effects

Enhancements

Distortions

Geometry

Hallucinatory states

Auditory effects

Toxicity and harm potential

Lethal dosage

The toxicity and long-term health effects of recreational escaline use do not seem to have been studied in any scientific context and the median lethal dose (LD50) is unknown. This is because escaline is a research chemical with very little history of human usage. Anecdotal evidence from those who have used escaline would suggest that there are little to no immediate or short-term negative health effects attributed to simply trying the drug at low to moderate doses or using it very sparingly. The validity of these statements, however, cannot be confirmed.

Tolerance and addiction potential

The addictive potential of escaline has not yet been formally studied, but anecdotal evidence would suggest that escaline is not physically addictive. Many users describe a self-regulating quality and commonly report a tolerance build up when using the drug consecutively many days in a row. A build up in tolerance may lead to weakened effects and a diminished experience; however, this effect is nearly non-existent when consumption periods are spaced 5-7 days apart.

Legal issues

Handcuffs-300px.png

This legality section is a stub.

As such, it likely contains incomplete or wrong information. You can help by expanding it.

  • United States: Escaline is unscheduled in the U.S., but may be illegal via the Federal Analog Act.

See also

External links

References

  1. www.erowid.org/library/books_online/pihkal/pihkal072.shtml | #72 E; ESCALINE
  2. https://www.erowid.org/archive/rhodium/chemistry/shulgin.pea.sar.hop.html | Psychotomimetic Drugs: Structure-Activity Relationships
  3. http://www.ncbi.nlm.nih.gov/pubmed/18666267 | Structure-activity relationships of phenylalkylamines as agonist ligands for 5-HT(2A) receptors.
  4. https://www.erowid.org/archive/rhodium/chemistry/shulgin.pea.sar.hop.html | Psychotomimetic Drugs: Structure-Activity Relationships